Trial Profile
A Randomized, Placebo-controlled Trial of Atomoxetine for Attention Deficit Hyperactivity Disorder in Adolescents With Substance Use Disorder (SUD)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 13 Jul 2015
Price :
$35
*
At a glance
- Drugs Atomoxetine (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Therapeutic Use
- 01 Jun 2010 Results have been published in the Journal of the American Academy of Child & Adolescent Psychiatry.
- 05 Oct 2008 Actual study completion date (Feb 2008) added as reported by ClinicalTrials.gov.
- 05 Oct 2008 Actual patient number (70) added as reported by ClinicalTrials.gov.